I think Genta will get there with Genansense. But what I find as NONsense is the financing the CEO put in place, a Convertible Preferred Class A stock convertible into 500,000 shares per $1000 principal=$.002 a share. The CEO owns many of these shares.

Also, there is a special vote ongoing which will dilute the shareholder’s stake in this company to a potential 1% of what it is now. The special vote is for a 1 for 100 Reverse Split, but still allows the company to keep the same number of shares issued or later REissued.

On top of that, the special shareholders meeting to vote on this is now back to back with a declaration of bankruptcy in June!

The CEO and the CFO for this company do not have the common shareholder’s stake best interests in mind.

Perhaps, if you wish to invest in this company, you might wait until the dust clears on all this financial NONsense and wait until the GNTA submits all its material for Genansense to the no-nonsense FDA in the fall!

I think Genta will get there with Genansense. But what I find as NONsense is the financing the CEO put in place, a Convertible Preferred Class A stock convertible into 500,000 shares per $1000 principal=$.002 a share. The CEO owns many of these shares.

Also, there is a special vote ongoing which will dilute the shareholder’s stake in this company to a potential 1% of what it is now. The special vote is for a 1 for 100 Reverse Split, but still allows the company to keep the same number of shares issued or later REissued.

On top of that, the special shareholders meeting to vote on this is now back to back with a declaration of bankruptcy in June!

The CEO and the CFO for this company do not have the common shareholder’s stake best interests in mind.

Perhaps, if you wish to invest in this company, you might wait until the dust clears on all this financial NONsense and wait until the GNTA submits all its material for Genansense to the no-nonsense FDA in the fall!